Search company, investor...
Silicos company logo

Silicos

silicos.com

Founded Year

2005

Stage

Other Investors | Alive

About Silicos

silicos aims to empower virtual screening for in silico drug discovery

Headquarters Location

Wetenschapspark 7

3590,

Germany

Missing: Silicos's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Silicos's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Silicos Patents

Silicos has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/4/2008

2/12/2013

Drug discovery, Cheminformatics, Medicinal chemistry, Computational chemistry, Designer drugs

Grant

Application Date

6/4/2008

Grant Date

2/12/2013

Title

Related Topics

Drug discovery, Cheminformatics, Medicinal chemistry, Computational chemistry, Designer drugs

Status

Grant

Silicos Frequently Asked Questions (FAQ)

  • When was Silicos founded?

    Silicos was founded in 2005.

  • What is Silicos's latest funding round?

    Silicos's latest funding round is Other Investors.

  • Who are the investors of Silicos?

    Investors of Silicos include Allegro Investment Fund, PMV, Vlaams Innovatiefonds, Gemma Frisius Fonds, LRM Capital and 3 more.

  • Who are Silicos's competitors?

    Competitors of Silicos include Oxford Drug Design, MerLion Pharmaceuticals, Nuevolution, Prosarix, 2cureX and 12 more.

Compare Silicos to Competitors

V
VivoPath

VivoPath is a preclinical screening company, offering the company's clients discovery and development services for in vivo testing. VivoPath aims to provide integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting program aims to deliver the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process. VivoPath's commitment is to provide scientific expertise in in vivo drug discovery in order to increase productivity from research into drug development.

M
MerLion Pharmaceuticals

MerLion Pharmaceuticals focuses on the discovery and development of drug candidates from natural sources. MerLion collaborates with leading pharmaceutical companies, biotechs and research institutes to identify and develop drug leads in a wide range of therapeutic areas.

G
Glycopep

Glycopep is engaged in the synthesis and development of unique chemicals and resin products to support drug discovery. Glycopep is providing custom synthesis to academic institutions and pharmaceutical/biotech companies.

C
CellMosaic

CellMosaic develops bioconjugates for research, manufacturing, biodection, discovery and diagnostics. The company's technologies lie at the interface of chemistry and biology, with special focus on synthetic organic chemistry and biochemistry. The company modify biopolymers or covalently link different biopolymers together through chemical or biochemical methods to create reagent-tools. Molecules the company work with include antibodies and their fragments, proteins (soluble and membrane proteins), enzymes, nucleic acids and their analogs, peptides and their mimetics (peptidomimetics), colorimetric or fluorescent compounds, biotin and avidin/streptavidin, solid support media, and other biologically active molecules.

A
AC PharmaChem

AC PharmaChem, Inc. is a fast growing company providing contract research and development services of medicinal chemistry, customer based organic synthesis of special chemical reagents, intermediates, reference compounds, and synthesis of focused libraries. The company's goal is to fully support the company's pharmaceutical and biotech partners to speed up and advance their drug discovery and innovation processes. At AC PharmaChem, the company have experienced medicinal and synthetic chemists utilizing synthetic techniques and instruments to provide cost efficient and on time delivery to meet the demands of the company's customers.

Oxford Drug Design Logo
Oxford Drug Design

Oxford Drug Design designs and develops small-molecule drugs against cancer, based on differentiated dual core competences. Its validated platform combines pioneering AI and machine learning methods with deep expertise in aminoacyl-tRNA synthetases, accelerating advances in the discovery and development of oncology therapeutics with novel mechanisms of action. It offers a its proprietary AI platform to pharmaceutical and biotechnology companies. Oxford Drug Design was founded in 2001 and is based in Oxford, England.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.